PVLA
Palvella Therapeutics, Inc.
NASDAQ · USHealthcareBiotechnology
$124.15-21.04%
Price as of Jul 20, 2026
PVLA growth
Palvella Therapeutics, Inc. growth
Reported trailing growth, forward expectations and three-year compound growth rates.
Trailing growth
Year over year
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- EPS
- +58.8%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
- Revenue
- —
- EBITDA
- +109.3%
- EPS
- -34.7%
Three-year CAGR
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- Net income
- —
- EPS
- +52.6%
- Free cash flow
- —
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.